BET-IN-20
BET-IN-20 (compound 10) is an inhibitor of BRD4 BD1 (IC50=1.9 nM) with anticancer activity. BET-IN-20 can promote acute myeloid leukemia (AML) cell apoptosis and arrest the cell cycle in the G0/G1 phase. BET-IN-20 also inhibits c-Myc and CDK6 and enhances PARP cleavage[1].
Product Specifications
CAS Number
[1300735-76-5]
UNSPSC
12352005
Target
Apoptosis; Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bet-in-20.html
Solubility
10 mM in DMSO
Smiles
C[C@H](C1=CC=CC=C1)N2C(C3=C4)=C(N=C2C)C=NC3=CC(C5=C(C)ON=C5C)=C4OC
Molecular Formula
C25H24N4O2
Molecular Weight
412.48
References & Citations
[1]Yu S et al. Discovery of (R) -4- (8-methoxy-2-methyl-1- (1-phenylethy) -1H-imidazo [4, 5-c] quinnolin-7-yl) -3, 5-dimethylisoxazole as a potent and selective BET inhibitor for treatment of acute myeloid leukemia (AML) guided by FEP calculation[J]. European Journal of Medicinal Chemistry, 2023: 115924.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items